전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,019 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#Melanoma+2
Trials 1Status Active
CGTLimited DatastaleZhujiang HospitalPhase 1

Sequential Treatment With different CART (Sequential Treatment With different CART)

Therapy Related Leukemia · Therapy Related Leukemia

#TherapyRelatedLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

sequential group (Sequential treatment of bevacizumab combined with atezolizumab, Sequential treatment of bevacizumab combined with atezolizumab (sequential group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleFirst Affiliated Hospital of We…Phase 2

Serplulimab immunotherapy (Serplulimab immunotherapy)

Locally Advanced Rectal Cancer (LARC) · Locally Advanced Rectal Cancer (LARC)

#LocallyAdvancedRectalCancerLARC#Antibody#Phase2#monoclonal-antibody#First
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

same period group (Simultaneous treatment of bevacizumab combined with atezolizumab, Simultaneous treatment of bevacizumab combined with atezolizumab (same period group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleInnoventPhase 2

PD-1 inhibitor (Sintilimab, Sintilimab (PD-1 inhibitor))

Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#LargeBCellDiffuseLymphoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleInnoventPhase 2

Sintilimab and Bevacizumab Combined with Radiotherapy (Sintilimab and Bevacizumab Combined with Radiotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Innovent
Trials 1Status Active
AntibodyLimited DatastaleInnoventPreclinical

Sintilimab combined with Bevacizumab (Sintilimab combined with Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Preclinical#monoclonal-antibody#Innovent
Trials 1Status Active
AntibodyLimited DatastaleMoonLake Immunotherapeutics AGPhase 2

Sonelokimab (Sonelokimab)

Arthritis, Psoriatic · Arthritis, Psoriatic

#ArthritisPsoriatic#Antibody#Phase2#monoclonal-antibody#Arthritis+2
Trials 1Status Active
AntibodyLimited DatastaleMoonLake Immunotherapeutics AGPhase 2

M1095 (Sonelokimab, Sonelokimab (M1095))

Hidradenitis Suppurativa · Hidradenitis Suppurativa

#HidradenitisSuppurativa#Antibody#Phase2#monoclonal-antibody#MoonLake
Trials 1Status Active
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 2

Standard Dose Bevacizumab (Standard Dose Bevacizumab)

Brain Cancer; Glioblastoma · Brain Cancer

#BrainCancer#Antibody#Phase2#monoclonal-antibody#Glioblastoma+1
Trials 1Status Active
AntibodyLimited DatastaleOslo University HospitalPhase 3

daratumumab (Darzalex, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#Oslo
Trials 1Status Recruiting
AntibodyLimited DatastaleRocheApproved

Subconjunctival Bevacizumab (Subconjunctival Bevacizumab)

Glaucoma · Glaucoma

#Glaucoma#Antibody#Approved#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePreclinical

Altuzan (Subconjunctival bevacizumab, Subconjunctival bevacizumab (Altuzan))

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Preclinical#monoclonal-antibody#Roche
Trials 1Status Active
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 1

Sup19 CAR-T (Sup19 CAR-T)

B-Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia/Lymphoma · B-Acute Lymphoblastic Leukemia

#B-AcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 1

Superselective Intraarterial Cerebral Infusion of Cetuximab (Superselective Intraarterial Cerebral Infusion of Cetuximab)

Glioblastoma Multiforme (GBM); ANAPLASTIC ASTROCYTOMA (AOA) · Glioblastoma Multiforme (GBM)

#GlioblastomaMultiformeGBM#Antibody#Phase1#monoclonal-antibody#ANAPLASTICASTROCYTOMAAOA+1
Trials 1Status Active
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting B7-H3 chimeric antigen receptor (T cell injection targeting B7-H3 chimeric antigen receptor)

B7-H3-positive Relapsed/ Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting FLT3 chimeric antigen receptor (T cell injection targeting FLT3 chimeric antigen receptor)

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

T cells modified with RNA anti -cMET CAR (T cells modified with RNA anti -cMET CAR)

Malignant Melanoma; Breast Cancer · Malignant Melanoma

#MalignantMelanoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 1

TACE combined with sintilimab and bevacizumab (TACE combined with sintilimab and bevacizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active

44 / 51 pages

← PreviousNext →